Form 8-K - Current report:
SEC Accession No. 0001104659-25-067785
Filing Date
2025-07-14
Accepted
2025-07-14 17:00:46
Documents
12
Period of Report
2025-07-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2520679d1_8k.htm   iXBRL 8-K 23517
  Complete submission text file 0001104659-25-067785.txt   188897

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tvrd-20250708.xsd EX-101.SCH 3044
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvrd-20250708_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvrd-20250708_pre.xml EX-101.PRE 22378
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2520679d1_8k_htm.xml XML 3695
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 251122336
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)